Novo Nordisk's Wegovy Receives FDA Approval for MASH, Boosts Stock Value

Novo Nordisk has secured FDA approval for its weight loss drug Wegovy to be used in treating metabolic dysfunction-associated steatotic liver disease (MASH). This new indication aligns with recommended lifestyle changes, including diet and exercise. MASH currently affects approximately 6% of adults in the United States, a prevalence that's rising, which could significantly increase the number of patients eligible for treatment.

Following the announcement on August 16, 2025, Novo Nordisk's stock price jumped approximately 7% in after-hours trading in the U.S., reflecting a positive market reaction. This approval is seen as a strategic advantage over its main competitor, Eli Lilly, which is developing similar therapies, including Mounjaro and Zepbound. The competitive landscape has intensified, especially considering that Novo Nordisk's stock value has halved in previous months amid growing competition from Eli Lilly.

Analyst Johan Wendel has noted that while Novo Nordisk faced significant challenges, he believes the stock has reached its lowest point, indicating potential for recovery. Novo Nordisk's Wegovy and Ozempic act as GLP-1 receptor agonists, which help regulate insulin and appetite, while Eli Lilly's therapies utilize tirzepatide with similar effects, indicating a robust battle for market share in the GLP-1 drug market, which is crucial for weight management and diabetes treatment.